Страна: Израиль
Язык: английский
Источник: Ministry of Health
FLURALANER
INTERVET ( ISRAEL) LTD
SPOT-ON SOLUTION
FLURALANER 280 MG / 1 ML
TOPICAL
Required
INTERVET INTERNATIONAL B.V. (MSD ANIMAL HEALTH), NETHERLANDS
For the treatment of tick and flea infestations in dogs.This veterinary medicinal product is a systemic insecticide and acaricide that provides:- immediate and persistent flea (Ctenocephalides felis and Ctenocephalides canis) killing activity for 12 weeks, and- immediate and persistent tick (Ixodes ricinus, Rhipicephalus sanguineus and Dermacentor reticulatus) killing activity for 12 weeks.Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).For the treatment of demodicosis caused by Demodex canis.For the treatment of sarcoptic mange (Sarcoptes scabiei var. canis) infestation.
2023-06-30
PATIENT LEAFLET FOR VETERINARY MEDICINAL PRODUCT This product is marketed with a veterinarian’s prescription only For use in animals only 1. NAME OF THE MEDICINAL PRODUCT: BRAVECTO 112.5 MG SPOT-ON SOLUTION VETERINARY DOGS BRAVECTO 250 MG SPOT-ON SOLUTION VETERINARY DOGS BRAVECTO 500 MG SPOT-ON SOLUTION VETERINARY DOGS BRAVECTO 1000 MG SPOT-ON SOLUTION VETERINARY DOGS BRAVECTO 1400 MG SPOT-ON SOLUTION VETERINARY DOGS Solution for topical use. 2. COMPOSITION: : substance Active Each ml contains 280 mg Fluralaner. Each pipette contains: FLURALANER (MG) PIPETTE CONTENT (ML) PRODUCT 112.5 0.4 BRAVECTO 112.5 MG SPOT-ON SOLUTION VETERINARY DOGS - For very small dogs (2-4.5 kg) 250 0.89 BRAVECTO 250 MG SPOT-ON SOLUTION VETERINARY DOGS - For small dogs (>4.5-10 kg) 500 1.79 BRAVECTO 500 MG SPOT-ON SOLUTION VETERINARY DOGS - For medium-sized dogs (>10-20 kg) 1,000 3.57 BRAVECTO 1000 MG SPOT-ON SOLUTION VETERINARY DOGS - For large dogs (>20-40 kg) 1,400 5.0 BRAVECTO 1400 MG SPOT-ON SOLUTION VETERINARY DOGS - For very large dogs (>40-56 kg) For the full list of excipients, see section 13 – "Additional information" 3. WHAT IS THE MEDICINAL PRODUCT INTENDED FOR: For the treatment of tick and flea infestations in dogs. This veterinary medicinal product is a systemic insecticide and acaricide that provides: - immediate and persistent flea (_Ctenocephalides felis_ and _Ctenocephalides _ _canis_) killing activity for 12 weeks, - immediate and persistent tick (_Ixodes ricinus_, _Rhipicephalus sanguineus_ and _Dermacentor reticulatus_) killing activity for 12 weeks. Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance. The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD). For the treatment of demodicosis caused by _Demodex canis_. For the treatment of sarcoptic mange (_Sarcoptes scabiei_ var. _canis_) infestation. Therapeutic group: Ectoparasiticides for systemic use. 4. CONTRAINDICATIONS: Do not use in case of hypersensit Прочитать полный документ
1. NAME OF THE VETERINARY MEDICINAL PRODUCT Bravecto 112.5 mg spot-on solution Veterinary Dogs Bravecto 250 mg spot-on solution Veterinary Dogs Bravecto 500 mg spot-on solution Veterinary Dogs Bravecto 1000 mg spot-on solution Veterinary Dogs Bravecto 1400 mg spot-on solution Veterinary Dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION ACTIVE SUBSTANCE: Each ml contains 280 mg fluralaner. Each pipette delivers: PIPETTE CONTENT FLURALANER (ML) (MG) for very small dogs 2 – 4.5 kg 0.4 112.5 for small dogs >4.5 – 10 kg 0.89 250 for medium-sized dogs >10 – 20 kg 1.79 500 for large dogs >20 – 40 kg 3.57 1000 for very large dogs >40 – 56 kg 5.0 1400 For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Spot-on-solution. Clear colourless to yellow solution. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the treatment of tick and flea infestations in dogs. This veterinary medicinal product is a systemic insecticide and acaricide that provides: - immediate and persistent flea ( _Ctenocephalides felis_ and _Ctenocephalides canis_ ) killing activity for 12 weeks, and - immediate and persistent tick ( _Ixodes ricinus, Rhipicephalus sanguineus_ and _Dermacentor_ _reticulatus_ ) killing activity for 12 weeks _._ Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance. The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD). For the treatment of demodicosis caused by _Demodex canis_ . For the treatment of sarcoptic mange ( _Sarcoptes scabiei_ var. _canis_ ) infestation. 4.3 CONTRAINDICATIONS Do not use in case of hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Parasites need to start feeding on the host to become exposed to fluralaner; therefore the risk of the transmission of parasite borne diseases cannot be excluded. 4.5 SPECIAL PRECAUTIONS FOR USE Spe Прочитать полный документ